VEGFR-3 Expression Profiling by Histology and Biomarkers Strategy to Classify Patient Population for the Selective VEGFR-3 Inhibitor EVT801

Recently presented by Evotec colleagues in collaboration with Kazia Therapeutics at the ESMO 2023 conference.

Download the poster

_{1 Oncopole IUCT, Toulouse, France}

_{2 Centre Léon Bérard, Lyon, France}

_{3 Evotec, Toulouse, France}

_{4 Kazia Therapeutics, Sydney, Australia}

_{*Corresponding author : pierre.fons@evotec.com}